Galena Biopharma (NASDAQ: GALE) and Astrazeneca PLC (NYSE:AZN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Insider and Institutional Ownership
20.5% of Galena Biopharma shares are owned by institutional investors. Comparatively, 14.2% of Astrazeneca PLC shares are owned by institutional investors. 0.8% of Galena Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current recommendations and price targets for Galena Biopharma and Astrazeneca PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Galena Biopharma currently has a consensus target price of $4.00, suggesting a potential upside of 1,328.57%. Astrazeneca PLC has a consensus target price of $36.60, suggesting a potential upside of 11.21%. Given Galena Biopharma’s higher possible upside, research analysts plainly believe Galena Biopharma is more favorable than Astrazeneca PLC.
Earnings and Valuation
This table compares Galena Biopharma and Astrazeneca PLC’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Galena Biopharma||$9.32 million||1.37||-$23.54 million||($1.31)||-0.21|
|Astrazeneca PLC||$23.00 billion||3.62||$3.50 billion||$2.79||11.80|
Astrazeneca PLC has higher revenue and earnings than Galena Biopharma. Galena Biopharma is trading at a lower price-to-earnings ratio than Astrazeneca PLC, indicating that it is currently the more affordable of the two stocks.
Astrazeneca PLC pays an annual dividend of $1.37 per share and has a dividend yield of 4.2%. Galena Biopharma does not pay a dividend. Astrazeneca PLC pays out 49.1% of its earnings in the form of a dividend.
Risk & Volatility
Galena Biopharma has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Astrazeneca PLC has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
This table compares Galena Biopharma and Astrazeneca PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Astrazeneca PLC beats Galena Biopharma on 10 of the 15 factors compared between the two stocks.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.